本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏艾迪药业集团股份有限公司（以下简称"公司"）第三届董事会第五次 会议通知于 2025 年 8 月 11 日以书面或电子邮件方式送达全体董事，会议于 2025 年 8 月 14 日在公司会议室以现场结合通讯表决方式召开。本次会议由董事长傅 和亮先生主持，应到董事 7 名，实到董事 7 名。本次会议的召集和召开程序符合 《中华人民共和国公司法》和《公司章程》等相关规定。 二、董事会会议审议情况 与会董事就如下议案进行了审议，并表决通过以下事项： （一）审议通过《关于调整 2025 年股票期权激励计划相关事项的议案》 证券代码：688488 证券简称：艾迪药业 公告编号：2025-042 江苏艾迪药业集团股份有限公司 第三届董事会第五次会议决议公告 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《艾迪药业关于向 2025 年股票期权激励计划激励对象首次授予股票期权的公告》 （公告编号：2025-045）。本议案已经公司 ...

2024年1至12月份，艾迪药业的营业收入构成为：药品制造占比71.59%，生物医药原辅料占比27.07%， 医疗器械占比0.8%，其他业务占比0.54%。 （文章来源：每日经济新闻） 艾迪药业（SH 688488，收盘价：16.8元）8月14日晚间发布公告称，公司第三届第五次董事会会议于 2025年8月14日在公司会议室以现场结合通讯表决方式召开。会议审议了《关于调整2025年股票期权激 励计划相关事项的议案》等文件。 ...

格隆汇8月14日丨艾迪药业(688488.SH)公布，公司于2025年8月14日召开第三届董事会第五次会议和第三届监事会第五次会议，审议通过了《关于调整2025年股票期权激励计划相关事项的议 ...

Market Overview - The biopharmaceutical sector increased by 0.55% on August 4, with Sairun Biotech leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in Biopharmaceutical Sector - Sairun Biotech (688163) closed at 27.37, up 11.90% with a trading volume of 72,700 shares and a transaction value of 190 million [1] - Xizang Pharmaceutical (600211) closed at 46.19, up 10.00% with a trading volume of 321,400 shares and a transaction value of 1.451 billion [1] - Wanze Shares (000534) closed at 17.31, up 9.97% with a trading volume of 598,100 shares and a transaction value of 1.018 billion [1] - Other notable gainers include Saiseng Pharmaceutical (300485) and Sanyuan Gene (837344) with increases of 7.45% and 6.89% respectively [1] Top Losers in Biopharmaceutical Sector - Kexing Pharmaceutical (688136) closed at 50.20, down 9.42% with a trading volume of 129,900 shares and a transaction value of 655 million [2] - Aopumai (688293) closed at 57.00, down 6.56% with a trading volume of 20,800 shares and a transaction value of 119 million [2] - Other significant decliners include Wuxi Jinghai (836547) and Olin Biotech (688319) with decreases of 3.28% and 3.22% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 10.35 million from institutional investors, while retail investors contributed a net inflow of 250 million [2][3] - Notable net inflows from individual stocks include Ganjin Pharmaceutical (603087) with 18.6 million and Xizang Pharmaceutical (600211) with 12.1 million [3] - Conversely, significant net outflows were observed in stocks like Xizang Pharmaceutical and Wanze Shares, indicating a mixed sentiment among retail investors [3]

Group 1 - The A-share biopharmaceutical sector experienced a short-term surge, with Tian Tan Biological reaching the daily limit, and Wan Ze Shares previously hitting the limit as well [1] - Other companies such as Aidi Pharmaceutical, Zhifei Biological, Boya Biological, Bohui Innovation, and Pailin Biological also saw increases in their stock prices [1] - The news is driven by the completion of China's first copy-type Tian Tan smallpox vaccine carrier HIV vaccine Phase I clinical trial by teams from the Chinese Center for Disease Control and Prevention and the AIDS Prevention Center [1]

Group 1 - The biopharmaceutical sector experienced a short-term surge, with TianTan Bio reaching the daily limit increase [1] - WanZe Co. previously hit the limit up, indicating strong market interest [1] - Other companies such as Aidi Pharmaceutical, ZhiFei Biological, BoYa Bio, BoHui Innovation, and PaiLin Bio also saw significant gains [1]

Group 1 - Zhejiang Dingli achieved a net profit of 1.051 billion yuan in the first half of 2025, a year-on-year increase of 27.49% [1] - The company reported an operating income of 4.336 billion yuan, representing a year-on-year growth of 12.35% [1] - Basic earnings per share were 2.08 yuan [1] Group 2 - Dexin Technology announced that its shareholder plans to reduce its stake by no more than 1%, equating to 2.3351 million shares [1] - The company specializes in the research, design, manufacturing, and sales of lithium battery cutting molds and precision components [1] Group 3 - Fangda Group signed new orders worth 970 million yuan in the second quarter of 2025 [1] - The total amount of signed but uncompleted contracts reached 4.916 billion yuan by the end of the second quarter [1] Group 4 - Warner Pharmaceutical's shareholder plans to reduce its stake by no more than 1.3 million shares, which is approximately 0.9899% of the total share capital [3] - The company focuses on the research, production, and sales of chemical raw materials and traditional Chinese medicine [3] Group 5 - Zijin Mining's vice president plans to reduce his holdings by no more than 250,300 shares [4] - The company is engaged in the exploration and development of mineral resources, including gold, copper, and lithium [4] Group 6 - Shenkong Co. received government subsidies totaling 14.9 million yuan [6] - The company specializes in the research, production, and sales of large-diameter silicon materials and semiconductor products [6] Group 7 - Jincai Hulin's shareholder plans to reduce its stake by no more than 2.5%, which amounts to 19.4798 million shares [1] - The company is involved in heat treatment equipment manufacturing and related services [1] Group 8 - New Media Co. plans to reduce its stake by no more than 6.8434 million shares, approximately 2.99% of the total share capital [1] - The company focuses on IPTV, internet audio-visual services, and content copyright [1] Group 9 - Aidi Pharmaceutical received a drug registration certificate for its product in Zanzibar, allowing for commercial sales [8] - The product is a new drug developed for the treatment of HIV-1 infection [8] Group 10 - Changlan Technology plans to reduce its stake by no more than 1%, equating to 1.9311 million shares [10] - The company specializes in the research, production, and sales of power cable accessories [10] Group 11 - Qiaofeng Intelligent announced that two shareholders plan to reduce their holdings by no more than 2.14% of the total share capital [12] - The company focuses on the research, production, and sales of CNC machine tools [12] Group 12 - Junxin Co. signed a tripartite preliminary agreement to build a solid waste disposal power facility valued at approximately 280 million USD in Almaty [13] - The company specializes in waste incineration power generation and related environmental services [13] Group 13 - Qinglong Pipe Industry signed a strategic cooperation framework agreement with Tian Shan High-tech [14] - The company is involved in the research, production, and sales of high-quality water supply pipes [14] Group 14 - Defang Nano's shareholder plans to reduce its stake by no more than 1%, equating to 2.7954 million shares [1] - The company specializes in the research, production, and sales of lithium-ion battery materials [1] Group 15 - ST Lutong's specific shareholder plans to reduce its stake by up to 3%, including 2 million shares through centralized bidding and 4 million shares through block trading [1] - The company focuses on cable television network equipment and smart control systems [1] Group 16 - Tongzhou Electronics reported a net profit of 203 million yuan in the first half of 2025, a significant turnaround from a loss of 36.08 million yuan in the previous year [17] - The company achieved an operating income of approximately 540 million yuan, representing a year-on-year growth of 606.52% [17] Group 17 - Rebecca reported a net profit of 9.3759 million yuan in the first half of 2025, a year-on-year increase of 15.31% [18] - The company achieved total operating revenue of approximately 598 million yuan, reflecting a year-on-year growth of 4.20% [18] Group 18 - Ruixin Technology's shareholders plan to reduce their holdings by no more than 4.9493 million shares, which is up to 3% of the total share capital [20] - The company specializes in the research, production, and sales of precision aluminum alloy components [20]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-040 江苏艾迪药业集团股份有限公司 关于艾诺米替片获得桑给巴尔药品注册证书的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司（以下简称"公司"）于近日收到桑给巴尔 （非洲坦桑尼亚联合共和国的组成部分）食品和药品管理局（ZANZIBAR FOOD AND DRUG AGENCY）于 2025 年 7 月 25 日核准签发的艾诺米替片《药品注册 证书》。现将相关情况公告如下： 一、药品注册的基本情况 药品商品名：Aitribond（桑给巴尔当地药品注册名） 规格：艾诺韦林 150mg，拉米夫定 300mg，富马酸替诺福韦二吡呋酯 300mg 药品批准文号：ZNZ76, AR27 JIA 药品注册证书有效期限至：2030 年 7 月 24 日 上市许可持有人：江苏艾迪药业股份有限公司 药品生产企业：江苏艾迪药业股份有限公司 二、药品其他情况 艾诺米替片系公司开发的具有自主知识产权的三联单片复方抗 HIV-1 感染 化学 ...

江苏艾迪药业集团股份有限公司（以下简称"公司"）于近日收到桑给巴尔 （非洲坦桑尼亚联合共和国的组成部分）食品和药品管理局（ZANZIBAR FOOD AND DRUG AGENCY）于 2025 年 7 月 25 日核准签发的艾诺米替片《药品注册 证书》。现将相关情况公告如下： 一、药品注册的基本情况 药品商品名：Aitribond（桑给巴尔当地药品注册名） 证券代码：688488 证券简称：艾迪药业 公告编号：2025-040 江苏艾迪药业集团股份有限公司 关于艾诺米替片获得桑给巴尔药品注册证书的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 规格：艾诺韦林 150mg，拉米夫定 300mg，富马酸替诺福韦二吡呋酯 300mg 药品批准文号：ZNZ76, AR27 JIA 药品注册证书有效期限至：2030 年 7 月 24 日 上市许可持有人：江苏艾迪药业股份有限公司 药品生产企业：江苏艾迪药业股份有限公司 二、药品其他情况 艾诺米替片系公司开发的具有自主知识产权的三联单片复方抗 HIV-1 感染 化学 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for investment [3][7]. Core Insights - The domestic HIV drug market is experiencing rapid growth, driven primarily by oral combination tablets. The market size for HIV drugs in China is projected to exceed 11 billion yuan by 2027, with a compound annual growth rate of 27% from 2017 to 2023 [6][50]. - The company has a multi-targeted approach in its HIV treatment drug pipeline, addressing diverse patient needs. Key products include the oral non-nucleoside reverse transcriptase inhibitors, which have been approved and included in the national medical insurance directory, leading to significant sales growth [6][7]. - The company is also focusing on developing long-acting pre-exposure prophylaxis (PrEP) drugs, which have substantial market potential in the U.S. market, estimated to be in the tens of billions of dollars [6][7]. Financial Data and Profit Forecast - The company is expected to achieve total revenue of 806 million yuan in 2025, with a year-on-year growth rate of 92.8%. By 2027, revenue is projected to reach 1.263 billion yuan [2]. - The net profit attributable to the parent company is forecasted to be 7 million yuan in 2025, with significant growth anticipated in subsequent years, reaching 166 million yuan by 2027 [2]. - The gross profit margin is expected to improve from 63.2% in 2025 to 75.2% by 2027, reflecting enhanced operational efficiency [2]. Company Overview - The company, established in 2009, specializes in the research, development, production, and sales of pharmaceutical products, focusing on HIV and human protein fields. It has established a strong competitive position in the domestic HIV market [14][23]. - The acquisition of Nanda Pharmaceutical in 2024 is part of the company's strategy to integrate human protein raw materials and formulations, enhancing its product offerings and market reach [28][32]. Market Dynamics - The report highlights the shift in the HIV drug market from government procurement to a combination of government-funded treatments, medical insurance, and out-of-pocket expenses, indicating a more diversified market structure [50][52]. - The company’s HIV drugs are expected to become mainstream products in the domestic market due to their superior efficacy and convenience compared to older government-procured drugs [6][9].